MAURICIO SIMOES ABRAO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
bookPart Endometriose: modelo experimental(2014) PODGAEC, Sergio; ABRãO, Maurício Simões; JúNIOR, José Maria Soares; SIMõES, Manuel de Jesus; BARACAT, Edmund ChadabookPart Endometriose - aspectos imunológicos e moleculares(2014) FERNANDES, Luiz Flávio Cordeiro; PODGAEC, Sérgio; ABRãO, Maurício Simões- Fatores ambientais e endometriose: um ponto de vista(2014) BELLELIS, Patrick; PODGAEC, Sergio; ABRÃO, Mauricio Simões
- Foxp3 expression in deep rectosigmoid endometriosis lesions and its association with chronic pelvic pain(2014) PODGAEC, Sergio; BARBEIRO, Denise Frediani; GUEUVOGHLANIAN-SILVA, Barbara Yasmin; BELLELIS, Patrick; ABRAO, Mauricio Simoes; BARACAT, Edmund ChadaEndometriosis is a benign gynecological disease that is related to immune response alterations. T regulatory cells modulate immune response, and Foxp3 seems to be the best marker of these cells. This study evaluated Foxp3 mRNA expression in eutopic endometrium from women with endometriosis and healthy controls, and its expression in deep rectosigmoid endometriosis lesions, one of the more aggressive types of the disease. Foxp3 expression was higher in lesions than in eutopic endometrium in the two groups. Moreover, eutopic endometrium Foxp3 expression of women with endometriosis was associated with chronic pelvic pain and cyclic urinary pain.
- Role of vascular endothelial growth factor polymorphisms (-2578C > A,-460 T > C,-1154G > A,+405G > C and+936C > T) in endometriosis: a case-control study with Brazilians(2014) PERINI, Jamila Alessandra; CARDOSO, Jessica Vilarinho; BERARDO, Plinio Tostes; VIANNA-JORGE, Rosane; NASCIUTTI, Luiz Eurico; BELLODI-PRIVATO, Marta; MACHADO, Daniel Escorsim; ABRAO, Mauricio SimoesBackground: Endometriosis is regarded as a complex and heterogeneous disease in which genetic and eri'jironr>ental factors contribute to the phenotype. The Vascular Endothelial Growth Factor (VEGF) plays important roles in the pathogenesis of endometriosis. The present study was aimed at investigating the contribution of VEGF polymorphisms as risk factors for the development of endometriosis. This is the first study to evaluate the combined influence of the five roost common VEGF polyroorphisms. Methods: This study was conducted at two hospitals from the Brazilian public health system, and comprised 294 vvomen submitted to laparoscopic or laparotomy surgery: 182 patients had a histologically confirmed diagnosis of endometriosis (cases), whereas 112 had no evidence of the disease (controls). The VEGF polymorphisms were determined by TagMan cal time polymerase chain reaction. The odds ratio (OR) with their 957o confidence intervals (Cl) were calculated using an unconditional logistic regression model. Results: Endometriosis patients and controls did not differ regarding age distribution, whereas the body mass index was significantly lower in enciometriosis patients, when compared with controls (23.1 3.9 versus 27.3 5.9, P <0001). The evaluation of gynecological symptoms, including dysmenorrhea, non cyclic chronic pelvic pain, dyspareunia and infertility, indicates significantly higher prevalences among endometriosis cases. The variant allele -1154A was significantly associated with endometriosis, either considering all cases (OR: 1.90, 95% Cl: 1.23 2.97), deep infiltrating endometriosis (DIE) (OR: 1.83, 95% Cl: 1.16-2.90) or moderate and severe endometriosis (stages Ill l5 (OR: 1.97, 95% Cl: 1.21-3.19). No significant differences were found in allele or genotype distributions of the 2578C > A, 460 T> C, +4070> C and +9,36C > T polymorphisms between endometriosis cases and controls. A total of six haplotypes were inferred derived from four polymorphisms (-2578C > A, 460 T> C, 1 1540 > A and +4050> C). There was a protective association between CCGG haplotype and endometriosis, either considering all cases (OR: 0.36, 95% Cl: 0.15-0.86), DIE (OR: 0.37 95% Cl: 0.15 0.90) or stages Ill IV (OR: 0.35 953 Cl: 0.13 ---- 0.95). Conclusions: The present results indicate a positive association between VEGF '11540 > A and the risk of developing endometriosis, whereas the CCGG haplotype may be protective against the development of disease.
- Reply: Biochemical markers for endometriosis: a long way to go(2014) BORRELLI, G. M.; ABRAO, M. S.; MECHSNER, S.
- Increased expression of antimullerian hormone and its receptor in endometriosis(2014) CARRARELLI, Patrizia; ROCHA, Ana Luiza Lunardi; BELMONTE, Giuseppe; ZUPI, Errico; ABRAO, Mauricio Simoes; ARCURI, Felice; PIOMBONI, Paola; PETRAGLIA, FeliceObjective: To evaluate antimullerian hormone (AMH) and AMH receptor II (AMHRII) mRNA and protein expression in endometrium and in ovarian or deep lesions of women with endometriosis. Design: Prospective study. Setting: University hospitals in Italy and Brazil. Patients: Patients with endometriosis (n = 55) and healthy women (n = 45). Interventions: Specimens of endometrium obtained by hysteroscopy from patients with endometriosis and from healthy control subjects; specimens of ovarian endometriosis (n = 29) or of deep endometriosis (n = 26) were collected by laparoscopy. Serum samples were collected in some endometriotic patients (n = 23) and healthy control subjects (n = 20). Main Outcome Measure(s): AMH and AMHRII mRNA levels were evaluated by quantitative reverse-transcription polymerase chain reaction and protein localization by immunohistochemistry. AMH levels in tissue homogenates and in serum were assessed by ELISA. Result(s): Endometrium from women with endometriosis showed higher AMH and AMHRII mRNA levels than control women, with no significant differences between proliferative and secretory phases. Specimens collected from ovarian or deep endometriosis showed the highest AMH and AMHRII mRNA expression. Immunolocalization study confirmed the high AMH and AMHRII protein expression in endometriotic lesions. No difference of serum AMH levels between the groups was found. Conclusion(s): The increased AMH and AMHRII mRNA and protein expression in endometrium and in endometriotic lesions suggests a possible involvement of AMH in endometriosis. (C) 2014 by American Society for Reproductive Medicine.
- Cellular, Histologic, and Molecular Changes Associated With Endometriosis and Ovarian Cancer(2014) NETO, Joao Siufi; KHO, Rosanne M.; SIUFI, Daniela Freitas dos Santos; BARACAT, Edmund Chada; ANDERSON, Karen S.; ABRAO, Mauricio SimoesOur understanding of the pathogenesis of endometriosis is rapidly evolving as early molecular events are increasingly identified. Endometriosis is associated with increased risk of ovarian cancer and exhibits neoplastic phenotypes including invasion of stromal tissue and lymphatic spread to distant organs. This review of the literature establishes the clinical, epidemiologic, and pathologic correlation between endometriosis and low-grade ovarian cancer. Genetic studies have demonstrated that endometriotic lesions have mutations in genes directly related to neoplasms, in particular the p53, KRAS, PTEN, and ARID1A genes, which suggests a direct transition from a subset of endometriotic lesions to invasive carcinomas. The identification of both genetic and epigenetic biomarkers including microRNAs are essential for identifying patients at risk for the transition to neoplasia.
- Can chemokines be used as biomarkers for endometriosis? A systematic review(2014) BORRELLI, G. M.; ABRAO, M. S.; MECHSNER, S.Can we use chemokines as biomarkers to diagnose patients with endometriosis in clinical practice? Some chemokines, especially CXCL8 (IL-8), CCL-2 (MCP-1) and CCL5 (RANTES), have the potential to work as biomarkers to identify patients with endometriosis but their accuracy could be improved by combination with other non-inflammatory markers in a panel of biomarkers. The need for a good marker to diagnose endometriosis has increased in recent years and research in this field has intensified. Chemokines have been reported to be associated with endometriosis in several studies over the last 20 years. Many of these studies measured one or more chemokines in peritoneal fluid (PF) and peripheral blood (PB) or through endometrial biopsies in patients with and without endometriosis. A systematic review was done on all published studies that compared chemokine concentrations in patients with and without endometriosis to evaluate their potential as biomarkers for the disease. Using MEDLINE database from December 1993 to August 2013 and the MeSH terms Endometriosis and Chemokines, we identified relevant studies to include in the present review, which was based on the PRISMA statement. Studies that measured at least one chemokine in patients with endometriosis and matching controls in PB, PF or endometrial samples were included. We did not include samples from ectopic lesions. All review articles as well as studies with animals and those not written in English were excluded from this systematic review. The studies were assessed using a modified version of the Quality Assessment of Diagnostic Accuracy Studies criteria. Two authors independently assessed studies for inclusion and risk of bias, and extracted data. After inclusion and exclusion criteria, 62 studies were selected to be included in this systematic review. A total of 27 different chemokines or their receptors were evaluated in the reviewed studies. The most studied chemokines (including their receptors) were CXCL8 (51.6), CCL2 (38.7) and CCL5 (19.3) ( of studies). CXCL8 (IL-8) appears to have the best results among all the other chemokines as a marker for endometriosis. Some studies included have low power due to small sample size and study designs vary in the assessment criteria for the markers, the state of the patients (e.g. phase of the cycle and stage of disease) and the nature of the controls. Our findings could guide future research in this field to select the chemokines with the best potential, and to stimulate better-designed studies to determine whether they can become a useful diagnostic tool in clinical practice. There was no funding to support this systematic review. The authors have no competing interest to declare.
- Could statins constitute a novel treatment for endometriosis? Systematic review of the literature(2014) GIBRAN, Luciano; MARANHAO, Raul C.; ABRAO, Mauricio S.; BARACAT, Edmundo C.; PODGAEC, SergioEndometriosis, defined as the presence of endometrial glands and/or stroma outside the uterine cavity, is an estrogen-dependent disease that affects about 10% of reproductive age women. Theories to explain the etiology of endometriosis abound. These include the alteration of epithelial cells on peritoneal surface, metaplasia of embryonic remnants of the mullerian ducts, immune system abnormalities, and the dissemination of endometrial cells through the circulation or lymphatic system, as well as retrograde menstruation, the hypothesis currently favored for the development of endometriosis. Angiogenesis, the development of new capillaries from pre-existing blood vessels, has been proposed as a key mechanism in the pathogenesis of endometriosis. Again from an etiological perspective, the formation of endometriotic implants requires ectopic fixation and proliferation of endometrial stroma and glands. The process of invasive insertion of endometriotic tissues involves the degradation of the extracellular matrix, and altered expression of matrix metalloproteinases (MMPs) in the eutopic and ectopic endometrium. Considering the antiproliferative, antiangiogenic, antioxidant, anti-inflammatory properties and matrix metalloproteinase activity inhibition of statins and the original studies addressing the possible mechanisms of action in endometriosis, the aim of this systematic review was to synthesize the research conducted to date in order to propose statins as possible and effective tools for controlling this disease.